Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species

NCT05101187 is registered in ClinicalTrials.gov with F2G Ltd as lead sponsor.

NCT NCT05101187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
Lead sponsor
F2G Ltd
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2022
Completion date
March 19, 2026
Enrollment
225 (actual)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis